Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

Andrzej Hellmann MD, PhDProf. Andrejz Hellmann
Head of the Department of Hematology

University of Gdańsk, Poland

Andrzej Hellmann is Professor of Medicine and head of the Department of Hematology of Medical University of Gdańsk since 1991. He received his medical degree in 1971 and PhD in 1976 from Medical University of Gdańsk.
Dr Hellmann completed a postdoctoral fellowship in leukemia biology at the Hammersmith Hospital in London in 1978 – 80. He is a specialist in internal medicine, hematology and clinical transplantology.  From 1982 to 1990 he was associate professor at Department of Medicine. In 1991 he organized and was appointed head of the new established Department of Hematology with BMT Unit at University of Gdańsk. Prof. Hellmann is author and co- author of more than 300 peer–reviewed articles in medical journals including NEJM and Blood. During a period 2005 – 2008 Prof. Hellmann was acting as a vice – rector of Medical University of Gdańsk. From   2003 till 2011Prof. Hellmann was the president of the Polish Society of Hematology and Transfusion Medicine. He is also the chairman of CML Study Group within the Polish Adult Leukemia Group. He is also the member of European Leukemia Network, American Society of Hematology, European Hematology Association, European Group for Blood and Marrow Transplantation, and International Society of Hematology. His special practical and research interest is still focused on myeloproliferative neoplasms.

             

 

 

Professor Peter Valent, MDFOTO VALENT

Senior Researcher and Senior Clinician 
Medical University of Vienna, Austria 

 

Professor Dr. Peter Valent is M.D. and a Senior Researcher as well as Senior Clinician at the Medical University of Vienna, Austria. He is the Scientific Director of the Ludwig Boltzmann Cluster Oncology (LB-CO) and leads a Special Research Program on Myeloproliferative Neoplasms in his University. He also coordinates a Clinical Study Group working in the field of myeloid neoplasms (focusing on CML, MDS, AML and mastocytosis) and is head of the Outpatient Clinics and Hematology Ambulatory in his institution. Professor Valent also participates in several other Research Programs in Vienna, including one dedicated to Cardiovascular Biology (10 years) and one dedicated to Allergic Diseases (20 years). Professor Valent is coordinator of the Vienna Cancer Stem Cell Club (VCSCC), coordinator of an International Working Group on Eosinophil Disorders (ICOG-EO), and coordinator of the European Competence Network on Mastocytosis (ECNM). He also coordinates the CML-Platform and MDS-Platform of the Austrian Society for Hematology and Oncology (ÖGHO), runs a Center of Excellence of the MDS Foundation, a Center of Excellence and Reference Center of the ECNM, and a Reference Center in CML. During the past 15 years, Professor Valent has organized a number of scientific meetings in Vienna, including several Consensus Conferences on Diagnostic Criteria and Diagnostic Standards. A special focus in his research are neoplastic stem cells; the identification of novel markers and targets in myeloid neoplasms; the development of disease-related criteria and targeted drug therapies in myeloid neoplasms; and the evaluation of target interaction profiles and side effects of novel drugs. Professor Valent is member in diverse Medical Societies, including the American Society of Hematology (ASH), and serves on various editorial boards and as a reviewer in most top hematology journals. He published more than 500 peer-reviewed articles and numerous review articles in his areas of expertise, lectured widely in Europe, North America, and Japan, and received numerous scientific awards. His h index arrived at 74, first-author h index at 32, and total citations at >21,000.

 

 

Dr J Apperley 2010

Professor of Medicine Chair, Department of Haematology Hammersmith Hospital
Imperial College, London (UK)

Professor Jane Apperley is the Chair of the Department of Haematology at the Imperial College and the Chief of Service for Clinical Haematology at the Imperial College Healthcare NHS Trust in London, England. Jane Apperley served as the President of both the European Group of Blood and Marrow Transplantation and the British Society of Blood and Marrow Transplantation. She also serves on the Advisory Board of the Centre for International Blood and Marrow Transplant Research.

She qualified in Medicine from the University of Birmingham and after initial specialization in internal medicine she completed specialist training in hematology in Birmingham, London, Cambridge and Boston.

Her particular interests are the biology and management of CML, which has led to an extensive experience in stem cell transplantation and to the use of signal transduction inhibitors. Her group at the Hammersmith Hospital site has extensive experience in the use of the first- and second-generation TKI’s, particularly in the areas of molecular monitoring and mechanisms of drug resistance. She has a long-standing interest in the ways in which hematologic diseases and their treatment impact fertility, pregnancy, and fetal outcome.

mauro michael

Leader, Myeloproliferative Neoplasms (MPN) Program

Memorial Sloan-Kettering Cancer Center, New York

 

Professor Michael Mauro directs the Myeloproliferative Neoplasms (MPN) Program at the Memorial Sloan-Kettering Cancer Center in New York. He received his medical degree from Dartmouth Medical School and completed his residency and fellowship training at New York-Presbyterian Hospital/Weill Cornell Medical Center. For more than a decade he worked with Dr Brian Druker at the OHSU Knight Cancer Institute in Portland, Oregon with a focus on research in CML. There he directed the CML clinical trial program and was involved in the early development and sentinel clinical study of targeted therapy for CML. His clinical focus is in CML with interest in therapy optimization, novel therapies, treatment free remission and pregnancy/fertility, as well as other myeloproliferative neoplasms, including myelofibrosis, polycythemia and thrombocytosis and less common conditions such as eosinophillic and mast cell disorders.

 

Professor Francois-Xavier Mahon

Professor and Senior House Physician

University of Bordeaux, FranceDr Mahon

 

Professor Mahon gratuated in clinical hematology from the faculty of medicine, University of Bordeaux and received a PhD for his work on "Selection of Normal Cells in Chronic Myeloid Leukaemia". Professor Mahon has completed a Research Fellowship at the Imperial College in London (UK) and is a felllow of the American Society of Hematology (ASH), the European Hematology Association (EHA), the French Society of Hematology, and the European Investigators on CML Group (El-CML). He currently serves as the President of the French Group of CML (Fl-LMC) and today has authored or co-authored for than 160 articles in peer-reviewed journals.   

 

 

 

 

 

 

Jeff Lipton, PhD MD FRCPCJeff Lipton

Jeff Lipton is Professor of Medicine at the University of Toronto and Staff Physician on the Leukemia and Allogeneic Blood and Marrow Transplant Services at the Princess Margaret Hospital. He received and honors BSc in Biochemistry at the University of Calgary and went on to a PhD in Biochemistry at the University of Western Ontario. An MRC post-doctoral fellowship at the Weizmann Institute in Israel with Leo Sachs led to his developing interests in leukemia. After a short time as a junior staff at the University of Connecticut, he had a mid-life crisis and went back to Calgary to go to medical school, followed by a residency in Internal Medicine. He then completed sub-specialty training in Medical Oncology at the University of Toronto and stayed on at the PMH as a staff physician. His clinical practice is in chronic leukemias and bone marrow failure syndromes as well as allogeneic stem cell transplant. Research interests in particular are in CML and its therapy, outcomes and supportive care in BMT, and in the therapy of bone marrow failure syndromes. Jeff serves on the Unrelated Donor Transplant Advisory Board of OneMatch, Past President of the Canadian Bone Marrow Transplant Group (CBMTG), was an advisor to the Center for Research on Bone Marrow Transplantation (CIBMTR), has served on the Clinical Trials Group of the CBMTG, was Director of the Allogeneic Stem Cell Transplant Program at PMH, is Head of the CML Study Group at PMH and is on several international advisory boards relating to the therapy of CML including the International CML Foundations and the ELN and Canadian CML Guidelines Committee. He has authored or co-authored more than 250 peer reviewed papers and 350 abstracts.